jakavi
novartis pharma gmbh - germania - ruxolitinibum - compr. - 5 mg - inhibitori de protein-kinaza
klertis 12,5 mg
egis pharmaceuticals plc - ungaria - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sutent 12,5 mg
pfizer italia srl - italia - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sutent 25mg
pfizer italia srl - italia - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sutent 50 mg
pfizer italia srl - italia - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
inlyta
pfizer europe ma eeig - axitinib - carcinomul, celula renală - protein kinazei - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.
stivarga
bayer pharma ag - regorafenib - neoplasme colorectale - antineoplastic agents, protein kinase inhibitors - stivarga este indicat în monoterapie pentru tratamentul pacienților adulți cu:cancer colorectal metastatic (crc), care au fost tratați anterior cu, sau nu sunt considerați candidați pentru, disponibile terapii - acestea includ chimioterapie pe bază de fluoropirimidine, un anti-vegf terapie și un anti-egfr terapie;inoperabil sau metastatic tumori stromale gastro-intestinale (gist), care a progresat sau intoleranță la tratamentul anterior cu imatinib și sunitinib;carcinom hepatocelular (hcc), care au fost anterior tratați cu sorafenib.
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenți antineoplazici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
fluimucil 100 mg
zambon s.p.a. - italia - acetylcysteinum - gran. pt. sol. orala - 100mg - expectorante excl. combinatii cu antitusive mucolitice
fluimucil 200 mg
zambon s.p.a. - italia - acetylcysteinum - gran. pt. sol. orala - 200mg - expectorante excl. combinatii cu antitusive mucolitice